Detail akcie 10x Genomics Rg-A online

Business Summary: 10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, 10X Genomics Inc revenues increased 7% to $476.8M. Net loss decreased 80% to $27.3M. Revenues reflect Services segment increase of 39% to $24.3M, Consumables segment increase of 2% to $365.4M, United States segment increase of 7% to $267.6M, China segment increase of 29% to $55.2M. Lower net loss reflects Stock-based Compensation in R&D decrease of 25% to $38M (expense).